DRD5: A Drug Target / Disease Biomarker (G1816)

Target Name: DRD5

NCBI ID: G1816

DRD5

DRD5: A Drug Target / Disease Biomarker

DRD5, which stands for dopamine receptor subtype 5, is a protein that is expressed in the brain and is involved in the transmission of dopamine signals. It is a potential drug target for the treatment of various neurological disorders, including Parkinson's disease, addiction, and schizophrenia.

DRD5 is a transmembrane protein that is composed of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain is responsible for the protein's ability to interact with other cells and molecules, while the transmembrane region is responsible for the protein's ability to span the cell membrane and interact with intracellular signaling molecules. The intracellular domain is responsible for the protein's ability to interact with and modulate the activity of the brain's dopamine system.

DRD5 is involved in the transmission of dopamine signals through its ability to interact with dopamine receptors, which are found throughout the brain. These receptors are responsible for transmitting signals from the brain's dopamine system to other parts of the brain and for controlling various physiological processes, including movement, emotion, and motivation.

Research has shown that DRD5 is involved in the development and progression of various neurological disorders, including Parkinson's disease, addiction, and schizophrenia. For example, studies have shown that individuals with the genetic mutation responsible for Parkinson's disease have lower levels of DRD5 in their brains compared to individuals without the mutation. Additionally, research has shown that individuals with addiction or schizophrenia have higher levels of DRD5 in their brains compared to individuals without these conditions.

In addition to its involvement in the development and progression of neurological disorders, DRD5 is also a potential drug target for the treatment of these disorders. For example, some studies have shown that blocking DRD5 with small molecules has the potential to treat symptoms of Parkinson's disease and addiction. Additionally, DRD5 has also been shown to play a role in the treatment of schizophrenia, with some studies suggesting that blocking DRD5 with small molecules may be an effective treatment for this disorder.

Overall, DRD5 is a protein that is involved in the transmission of dopamine signals through its interaction with dopamine receptors. It is a potential drug target for the treatment of various neurological disorders, including Parkinson's disease, addiction, and schizophrenia. Further research is needed to fully understand the role of DRD5 in the development and progression of these disorders and to develop effective treatments.

Protein Name: Dopamine Receptor D5

Functions: Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

The "DRD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets